Next, the prognostic value of TMEindex for the ICI therapy was explored through two cohorts (IMvigor210-BLCA and IMvigor210-Kidney cancer) receiving anti-PD-L1 therapy. This evidence concerns the gene CD274 and bladder transitional cell carcinoma.